Table 1. Demographic and clinical characteristics of staff (n = 98) and patients (n = 333).
| Characteristic | IGRA positive | IGRA negative |
| n (%) | n (%) | |
| Staff | ||
| Characteristic | ||
| Total | 7 | 90 |
| No. (%) male | 1 (14.3) | 7 (7.8) |
| Age (yr) | ||
| Median | 45 | 41 |
| IQR | 32.5–52 | 33–46 |
| Country of birth [No. (%)] | ||
| UK | 6 (85.7) | 79 (87.8) |
| Non-UK (Canada, Germany, Philippines, Republic of Ireland) | 1 (14.3) | 10 (11.1) |
| Unknown | 0 (0) | 1 (1.1) |
| BCG vaccination status [No. (%)] | ||
| Vaccinated | 2 (28.6) | 76 (84.4) |
| Unknown | 0 | 6 (6.7) |
| TST (where age < = 35) [No. (%)] | ||
| Total | 2 | 32 |
| Positive (> = 15 mm induration) | 0 | 6 (18.8) |
| Unknown | 0 | 2 (6.25) |
| Co-morbidities [No. (%)] | ||
| Immunocompromised | 0 | 0 |
| HIV | 0 | 0 |
| Diabetes | 1 (14.3) | 0 |
| Previous TB contact | 3 (42.9) | 16 (17.8) |
| Patients | ||
| Characteristic | IGRA positive | IGRA negative |
| Total | 30 | 262 |
| No. (%) male | 17 (56.7) | 145 (55.3) |
| Age (yr) | ||
| Median | 70.5 | 64 |
| IQR | 65.5–74 | 45–77 |
| Co-morbidities [No. (%)] | ||
| Diabetes | 7 (23.3) | 64 (24.4) |
| Cancer | 8 (26.7) | 69 (26.3) |
| Immunosuppressive drugs/chemotherapy* | 1 (3.3) | 42 (16) |
| Steroids | 3 (10) | 41 (15.6) |
| Unknown | 1 (3.3) | 8 (3.1) |
| Any co-morbidity | 16 (53.3) | 165 (63) |